# Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

> **NCT01508910** · PHASE3 · COMPLETED · sponsor: **Lisata Therapeutics, Inc.** · enrollment: 291 (actual)

## Conditions studied

- Chronic Myocardial Ischemia
- Refractory Angina Pectoris
- Advanced Coronary Heart Disease

## Interventions

- **BIOLOGICAL:** Auto-CD34+ cells
- **BIOLOGICAL:** Placebo: Diluent used to suspend Auto-CD34+ cells
- **OTHER:** Standard of care

## Key facts

- **NCT ID:** NCT01508910
- **Lead sponsor:** Lisata Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 291 (ACTUAL)
- **Last updated:** 2018-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01508910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01508910, "Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01508910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*